Question 1
Which of the following is a common mechanism of action of calcineurin inhibitors such as cyclosporine and tacrolimus in immunosuppression?
A) Inhibition of DNA synthesis
B) Inhibition of T-cell activation by blocking IL-2 production
C) Stimulation of B-cell proliferation
D) Neutralization of TNF-alpha
E) Activation of macrophages
Correct Answer: B) Inhibition of T-cell activation by blocking IL-2 production
Explanation: Calcineurin inhibitors like cyclosporine and tacrolimus work by inhibiting the production of interleukin-2 (IL-2), which is crucial for T-cell activation and proliferation, thus providing immunosuppressive effects.
Question 2
Which of the following immunosuppressants is associated with nephrotoxicity as a significant side effect?
A) Azathioprine
B) Tacrolimus
C) Mycophenolate mofetil
D) Sirolimus
E) Prednisone
Correct Answer: B) Tacrolimus
Explanation: Tacrolimus, a calcineurin inhibitor, is associated with nephrotoxicity as a significant side effect, especially with prolonged use.
Question 3
Which of the following is a commonly used antiproliferative agent in organ transplant patients that inhibits purine synthesis?
A) Cyclosporine
B) Tacrolimus
C) Mycophenolate mofetil
D) Prednisone
E) Everolimus
Correct Answer: C) Mycophenolate mofetil
Explanation: Mycophenolate mofetil is an antiproliferative agent that inhibits purine synthesis, leading to a reduction in the proliferation of B and T lymphocytes. It is commonly used in organ transplant patients.
Question 4
Which of the following is a major side effect of corticosteroids when used long-term for immunosuppression?
A) Weight loss
B) Osteoporosis
C) Hyperkalemia
D) Hair loss
E) Nephrotoxicity
Correct Answer: B) Osteoporosis
Explanation: Long-term use of corticosteroids, such as prednisone, is associated with several side effects, including osteoporosis, weight gain, hyperglycemia, and an increased risk of infections.
Question 5
Which immunosuppressant carries a risk of hyperlipidemia and impaired wound healing, particularly when used in solid organ transplant patients?
A) Azathioprine
B) Mycophenolate mofetil
C) Cyclosporine
D) Sirolimus
E) Tacrolimus
Correct Answer: D) Sirolimus
Explanation: Sirolimus, an mTOR inhibitor, is associated with hyperlipidemia and impaired wound healing, making it a concern in patients who require solid organ transplants.
Question 6
Which of the following immunosuppressants is most likely to cause bone marrow suppression, including leukopenia and thrombocytopenia?
A) Cyclosporine
B) Azathioprine
C) Tacrolimus
D) Sirolimus
E) Prednisone
Correct Answer: B) Azathioprine
Explanation: Azathioprine is an antiproliferative agent that can cause bone marrow suppression, leading to leukopenia and thrombocytopenia, requiring careful monitoring of blood counts.
Question 7
A 50-year-old male with a kidney transplant is started on tacrolimus to prevent rejection. Which of the following side effects is most commonly associated with tacrolimus use?
A) Hyperlipidemia
B) Nephrotoxicity
C) Hyperkalemia
D) Osteoporosis
E) Weight gain
Correct Answer: B) Nephrotoxicity
Explanation: Tacrolimus is a calcineurin inhibitor commonly associated with nephrotoxicity. Monitoring renal function is critical in patients on tacrolimus therapy.
Question 8
A patient is receiving azathioprine for the treatment of systemic lupus erythematosus (SLE). Which of the following is an important laboratory test to monitor during treatment with azathioprine?
A) Liver function tests (LFTs)
B) Complete blood count (CBC)
C) Serum potassium levels
D) Blood glucose levels
E) Serum calcium levels
Correct Answer: B) Complete blood count (CBC)
Explanation: Azathioprine can cause bone marrow suppression, leading to leukopenia, thrombocytopenia, and anemia. Regular CBC monitoring is essential to detect these hematologic effects early.
Question 9
Which of the following immunosuppressant drugs inhibits purine synthesis by inhibiting inosine monophosphate dehydrogenase, leading to reduced lymphocyte proliferation?
A) Cyclosporine
B) Methotrexate
C) Mycophenolate mofetil
D) Azathioprine
E) Sirolimus
Correct Answer: C) Mycophenolate mofetil
Explanation: Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase, thereby reducing purine synthesis and decreasing lymphocyte proliferation. It is commonly used in transplant recipients to prevent rejection.
Question 10
A patient on cyclosporine therapy develops hypertension. Which of the following antihypertensive medications should be avoided due to the potential for increasing cyclosporine levels?
A) Lisinopril
B) Amlodipine
C) Metoprolol
D) Verapamil
E) Hydrochlorothiazide
Correct Answer: D) Verapamil
Explanation: Verapamil is a CYP3A4 inhibitor that can increase cyclosporine levels, leading to increased risk of toxicity, including nephrotoxicity and hypertension. It should be avoided or used with caution in patients on cyclosporine.
Question 11
A 35-year-old woman with Crohn’s disease is prescribed methotrexate. Which of the following should be included in the counseling for methotrexate use?
A) Take methotrexate daily for best results.
B) Folic acid supplementation should be taken with methotrexate to reduce toxicity.
C) Methotrexate is safe to use in pregnancy.
D) Methotrexate has no risk of liver toxicity.
E) Methotrexate does not require any lab monitoring.
Correct Answer: B) Folic acid supplementation should be taken with methotrexate to reduce toxicity.
Explanation: Methotrexate can cause folate depletion, leading to side effects like mucositis and myelosuppression. Folic acid supplementation is recommended to mitigate these toxicities.
Question 12
Which of the following side effects is more commonly associated with tacrolimus compared to cyclosporine?
A) Gingival hyperplasia
B) Hirsutism
C) Hyperglycemia/Diabetes
D) Hyperkalemia
E) Tremor
Correct Answer: C) Hyperglycemia/Diabetes
Explanation: Tacrolimus is associated with a higher risk of hyperglycemia and new-onset diabetes after transplantation compared to cyclosporine.
Question 13
Which of the following medications can increase the blood levels of calcineurin inhibitors like cyclosporine and tacrolimus by inhibiting CYP3A4?
A) Phenytoin
B) Rifampin
C) Ketoconazole
D) St. John’s Wort
E) Carbamazepine
Correct Answer: C) Ketoconazole
Explanation: Ketoconazole is a strong inhibitor of CYP3A4 and can increase the blood levels of calcineurin inhibitors like cyclosporine and tacrolimus, leading to an increased risk of toxicity.
Question 14
Which calcineurin inhibitor is often preferred in organ transplantation due to its more potent immunosuppressive effects and fewer cosmetic side effects?
A) Cyclosporine
B) Tacrolimus
C) Azathioprine
D) Mycophenolate mofetil
E) Sirolimus
Correct Answer: B) Tacrolimus
Explanation: Tacrolimus is often preferred over cyclosporine in organ transplantation due to its more potent immunosuppressive effects and fewer cosmetic side effects such as hirsutism and gingival hyperplasia.
Question 15
Which of the following is a unique side effect of cyclosporine not typically seen with tacrolimus?
A) Hyperglycemia
B) Nephrotoxicity
C) Gingival hyperplasia
D) Neurotoxicity
E) Hyperkalemia
Correct Answer: C) Gingival hyperplasia
Explanation: Gingival hyperplasia is a unique side effect of cyclosporine, characterized by the overgrowth of gum tissue, which is less common with tacrolimus.
Question 16
Which of the following drugs should be used with caution or avoided in a patient taking tacrolimus due to the risk of increasing tacrolimus levels?
A) Rifampin
B) Phenytoin
C) St. John’s Wort
D) Erythromycin
E) Carbamazepine
Correct Answer: D) Erythromycin
Explanation: Erythromycin is a CYP3A4 inhibitor, which can increase tacrolimus levels, potentially leading to toxicity, such as nephrotoxicity or neurotoxicity. Rifampin and other enzyme inducers would lower tacrolimus levels.
Question 17
A patient taking tacrolimus after a liver transplant develops new-onset diabetes mellitus. Which of the following best explains why tacrolimus may lead to this condition?
A) Tacrolimus increases insulin resistance.
B) Tacrolimus reduces insulin production by the pancreas.
C) Tacrolimus increases glucagon secretion.
D) Tacrolimus causes hyperkalemia, leading to insulin resistance.
E) Tacrolimus increases gluconeogenesis in the liver.
Correct Answer: B) Tacrolimus reduces insulin production by the pancreas.
Explanation: Tacrolimus can lead to new-onset diabetes after transplantation by directly affecting the pancreatic beta cells, reducing insulin production.
Question 18
Which of the following best describes the mechanism of action of mTOR inhibitors such as sirolimus and everolimus?
A) Inhibition of DNA synthesis in T cells
B) Inhibition of mTORC1 by binding to FKBP-12, affecting T-cell and B-cell proliferation
C) Stimulation of cytokine release from macrophages
D) Blockade of IL-2 receptors on T cells
E) Inhibition of TNF-alpha production
Correct Answer: B) Inhibition of mTORC1 by binding to FKBP-12, affecting T-cell and B-cell proliferation
Explanation: mTOR inhibitors, such as sirolimus and everolimus, bind to FKBP-12 and inhibit mTORC1, which leads to suppression of T-cell and B-cell proliferation and reduced immune response.
Question 19
Which of the following is a common side effect of mTOR inhibitors like sirolimus and everolimus?
A) Gingival hyperplasia
B) Hyperlipidemia
C) Hypoglycemia
D) Alopecia
E) Hypertension
Correct Answer: B) Hyperlipidemia
Explanation: mTOR inhibitors are commonly associated with hyperlipidemia, leading to elevated levels of cholesterol and triglycerides, which may require the use of lipid-lowering therapies.
Question 20
Which of the following conditions is sirolimus commonly indicated for?
A) Prevention of acute graft-versus-host disease
B) Prevention of organ rejection in kidney transplantation
C) Treatment of autoimmune diseases such as lupus
D) Management of Crohn’s disease
E) Maintenance of blood glucose levels in diabetes
Correct Answer: B) Prevention of organ rejection in kidney transplantation
Explanation: Sirolimus is primarily used to prevent organ rejection in kidney transplants, typically as part of a multi-drug regimen with other immunosuppressive agents.
Question 21
Which of the following cancers is everolimus approved to treat?
A) Colorectal cancer
B) Breast cancer
C) Ovarian cancer
D) Pancreatic neuroendocrine tumors
E) Prostate cancer
Correct Answer: D) Pancreatic neuroendocrine tumors
Explanation: Everolimus is approved for the treatment of various cancers, including pancreatic neuroendocrine tumors, renal cell carcinoma, breast cancer, and tuberous sclerosis complex-associated tumors.
Question 22
Which of the following is a rare but serious pulmonary complication of mTOR inhibitor therapy?
A) Pneumonia
B) Interstitial lung disease
C) Pulmonary embolism
D) Chronic obstructive pulmonary disease (COPD)
E) Asthma exacerbation
Correct Answer: B) Interstitial lung disease
Explanation: mTOR inhibitors, such as sirolimus and everolimus, can cause rare but serious pulmonary toxicity, including interstitial lung disease and pneumonitis.
Question 23
Which of the following side effects of mTOR inhibitors can impair recovery after surgery?
A) Anemia
B) Delayed wound healing
C) Hyperkalemia
D) Myalgia
E) Hair loss
Correct Answer: B) Delayed wound healing
Explanation: mTOR inhibitors inhibit cell proliferation, which can impair wound healing, making post-surgical recovery more difficult.
Question 24
A 45-year-old kidney transplant patient is started on an immunosuppressive regimen that includes basiliximab. What is the primary mechanism by which basiliximab helps prevent organ rejection?
A) Inhibits T-cell activation by binding to CD52
B) Inhibits T-cell activation by blocking IL-2 receptor (CD25)
C) Depletes B and T lymphocytes through antibody-dependent cellular cytotoxicity
D) Inhibits cytokine release by blocking TNF-alpha receptors
E) Reduces the number of T-cells by inducing apoptosis
Correct Answer: B) Inhibits T-cell activation by blocking IL-2 receptor (CD25)
Explanation: Basiliximab specifically targets and binds to the IL-2 receptor (CD25) on activated T-cells, thereby preventing T-cell activation and proliferation.
Question 25
Alemtuzumab is prescribed for a patient with multiple sclerosis to reduce the frequency of relapses. Which of the following is a significant risk associated with alemtuzumab therapy?
A) Gastrointestinal disturbances
B) Infusion-related reactions such as fever and chills
C) Pulmonary embolism
D) Hepatotoxicity
E) Hyperglycemia
Correct Answer: B) Infusion-related reactions such as fever and chills
Explanation: Alemtuzumab is known to cause infusion-related reactions such as fever, chills, and rash. Patients on alemtuzumab are also at increased risk for infections and cytopenias.
Question 26
A patient undergoing treatment with alemtuzumab for chronic lymphocytic leukemia (CLL) presents with signs of leukopenia and thrombocytopenia. Which mechanism of action explains this side effect?
A) Direct inhibition of IL-2 receptor
B) Depletion of CD52-positive cells through antibody-dependent cellular cytotoxicity
C) Blocking of TNF-alpha receptor
D) Inhibition of JAK-STAT pathway
E) Inhibition of T-cell proliferation
Correct Answer: B) Depletion of CD52-positive cells through antibody-dependent cellular cytotoxicity
Explanation: Alemtuzumab binds to CD52 on lymphocytes, leading to the destruction of these cells through antibody-dependent cellular cytotoxicity and complement-mediated lysis, which can result in leukopenia and thrombocytopenia.
Question 27
Which of the following best describes the primary mechanism of action of mycophenolate mofetil?
A) Inhibition of calcineurin
B) Inhibition of inosine monophosphate dehydrogenase (IMPDH), reducing purine synthesis
C) Suppression of IL-2 production
D) Blockade of TNF-alpha receptors
E) Activation of T-cells
Correct Answer: B) Inhibition of inosine monophosphate dehydrogenase (IMPDH), reducing purine synthesis
Explanation: Mycophenolate mofetil inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is crucial for the de novo synthesis of guanosine nucleotides, thereby selectively suppressing lymphocyte proliferation.
Question 28
Which of the following conditions is mycophenolate mofetil commonly used to treat?
A) Organ transplantation and lupus nephritis
B) Diabetes and hypertension
C) Hyperlipidemia and hypothyroidism
D) Chronic obstructive pulmonary disease (COPD) and asthma
E) Peptic ulcer disease and GERD
Correct Answer: A) Organ transplantation and lupus nephritis
Explanation: Mycophenolate mofetil is commonly used in the prevention of organ rejection in kidney, heart, or liver transplants and in the management of lupus nephritis due to its immunosuppressive properties.
Question 29
Which of the following is a significant risk associated with the use of mycophenolate mofetil during pregnancy?
A) Hypoglycemia
B) Teratogenicity and fetal harm
C) Hypercalcemia
D) Hypotension
E) Seizures
Correct Answer: B) Teratogenicity and fetal harm
Explanation: Mycophenolate mofetil is classified as Pregnancy Category D/X due to the risk of teratogenic effects, congenital malformations, and fetal harm. Women of childbearing potential should use effective contraception while on this medication.
Question 30
Which of the following side effects is commonly associated with mycophenolate mofetil and is often dose-limiting?
A) Hyperkalemia
B) Gastrointestinal side effects such as diarrhea and abdominal pain
C) Alopecia
D) Osteoporosis
E) Hyperlipidemia
Correct Answer: B) Gastrointestinal side effects such as diarrhea and abdominal pain
Explanation: Gastrointestinal side effects, including diarrhea, nausea, vomiting, and abdominal pain, are common and dose-limiting with mycophenolate mofetil. The enteric-coated formulation (Myfortic) is designed to reduce these side effects.
Question 31
Which of the following infections poses a rare but serious risk to patients taking mycophenolate mofetil?
A) Hepatitis C
B) Cytomegalovirus (CMV)
C) Progressive multifocal leukoencephalopathy (PML)
D) Human papillomavirus (HPV)
E) Tuberculosis
Correct Answer: C) Progressive multifocal leukoencephalopathy (PML)
Explanation: Progressive multifocal leukoencephalopathy (PML) is a rare but serious viral infection of the brain that can occur in patients taking immunosuppressive agents like mycophenolate mofetil.
Question 32
Which of the following drugs may reduce the absorption and efficacy of mycophenolate mofetil when taken together?
A) Acyclovir
B) Cyclosporine
C) Antacids and proton pump inhibitors (PPIs)
D) Rifampin
E) Tacrolimus
Correct Answer: C) Antacids and proton pump inhibitors (PPIs)
Explanation: Antacids containing aluminum or magnesium, and PPIs, can reduce the absorption of mycophenolate mofetil, potentially decreasing its efficacy.